Rathbones Group PLC increased its stake in ASP Isotopes Inc. (NASDAQ:ASPI – Free Report) by 68.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 399,599 shares of the company’s stock after buying an additional 162,535 shares during the quarter. Rathbones Group PLC owned about 0.36% of ASP Isotopes worth $2,138,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of ASPI. UBS Group AG grew its stake in shares of ASP Isotopes by 150.3% in the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after buying an additional 1,445,165 shares in the last quarter. Marshall Wace LLP grew its stake in shares of ASP Isotopes by 3,669.1% in the third quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock valued at $12,305,000 after buying an additional 1,245,184 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after buying an additional 1,241,024 shares in the last quarter. Rovida Investment Management Ltd grew its stake in shares of ASP Isotopes by 45.5% in the third quarter. Rovida Investment Management Ltd now owns 3,200,000 shares of the company’s stock valued at $30,688,000 after buying an additional 1,000,000 shares in the last quarter. Finally, Jump Financial LLC acquired a new stake in shares of ASP Isotopes in the third quarter valued at about $8,990,000. Institutional investors and hedge funds own 16.80% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.00.
Insider Activity at ASP Isotopes
In related news, CFO Heather Kiessling sold 23,124 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $5.48, for a total value of $126,719.52. Following the completion of the transaction, the chief financial officer owned 709,376 shares of the company’s stock, valued at approximately $3,887,380.48. This represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Robert Ainscow sold 25,000 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $4.51, for a total value of $112,750.00. Following the completion of the transaction, the chief operating officer directly owned 1,512,817 shares of the company’s stock, valued at $6,822,804.67. This represents a 1.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 90,704 shares of company stock valued at $463,252. Insiders own 14.40% of the company’s stock.
ASP Isotopes Trading Up 7.4%
Shares of ASPI opened at $5.55 on Friday. The company has a market capitalization of $698.75 million, a P/E ratio of -2.67 and a beta of 3.26. ASP Isotopes Inc. has a one year low of $3.92 and a one year high of $14.49. The company has a debt-to-equity ratio of 0.69, a quick ratio of 12.20 and a current ratio of 4.39. The stock has a 50-day moving average price of $5.06 and a 200 day moving average price of $5.95.
ASP Isotopes (NASDAQ:ASPI – Get Free Report) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. The firm had revenue of $8.36 million during the quarter, compared to the consensus estimate of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.
ASP Isotopes Company Profile
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Read More
- Five stocks we like better than ASP Isotopes
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Want to see what other hedge funds are holding ASPI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ASP Isotopes Inc. (NASDAQ:ASPI – Free Report).
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.
